John Ramunas and Glenn Markov lead Rejuvenation Technologies in its pursuit to treat age-related conditions. Their product, RTI-LIV, targets Compensated Cirrhosis, aiming to utilize telomere extension as a therapeutic approach against aging.
John Ramunas and Glenn Markov lead Rejuvenation Technologies in its pursuit to treat age-related conditions. Their product, RTI-LIV, targets Compensated Cirrhosis, aiming to utilize telomere extension as a therapeutic approach against aging.